Abstract
Background: The use of biologic agents in systemic immune-mediated diseases has dramatically increased in recent years, replacing conventional immunosuppressive strategies that are characterized by unspecific mechanisms of action and burdened with serious adverse effects. Biologic drugs have selective action towards specific targets, with considerable steroid-sparing effect. They are used nowadays to induce remission or treat specific organ involvements in systemic autoimmune diseases.
Conclusion: In this review, we will discuss the scientific evidence supporting the use of biologics in these diseases, with a particular emphasis on their efficacy and safety profile compared to the conventional drugs.
Keywords: ANCA-associated vasculitis, Behcet Disease, belimumab, rituximab, Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), TNF-inhibitors, tocilizumab.
Current Pharmaceutical Biotechnology
Title:Biologics in Inflammatory Immune-mediated Systemic Diseases
Volume: 18 Issue: 12
Author(s): Gianluca Moroncini*, Giovanni Calogera, Devis Benfaremo and Armando Gabrielli
Affiliation:
- Clinica Medica, Dipartimento di Scienze Cliniche e Molecolari, Universita Politecnica delle Marche, Ancona,Italy
Keywords: ANCA-associated vasculitis, Behcet Disease, belimumab, rituximab, Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), TNF-inhibitors, tocilizumab.
Abstract: Background: The use of biologic agents in systemic immune-mediated diseases has dramatically increased in recent years, replacing conventional immunosuppressive strategies that are characterized by unspecific mechanisms of action and burdened with serious adverse effects. Biologic drugs have selective action towards specific targets, with considerable steroid-sparing effect. They are used nowadays to induce remission or treat specific organ involvements in systemic autoimmune diseases.
Conclusion: In this review, we will discuss the scientific evidence supporting the use of biologics in these diseases, with a particular emphasis on their efficacy and safety profile compared to the conventional drugs.
Export Options
About this article
Cite this article as:
Moroncini Gianluca*, Calogera Giovanni , Benfaremo Devis and Gabrielli Armando , Biologics in Inflammatory Immune-mediated Systemic Diseases, Current Pharmaceutical Biotechnology 2017; 18 (12) . https://dx.doi.org/10.2174/1389201019666171226152448
DOI https://dx.doi.org/10.2174/1389201019666171226152448 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Design, Synthesis and In Vitro Release Studies of Co-Drugs for Rheumatoid Arthritis
Inflammation & Allergy - Drug Targets (Discontinued) Immunogenicity in Protein and Peptide Based-Therapeutics: An Overview
Current Protein & Peptide Science PROGRAMMED Cell Clearance: Molecular Mechanisms and Role in Autoimmune Disease, Chronic Inflammation, and Anti-Cancer Immune Responses
Current Immunology Reviews (Discontinued) “Something is Wrong in the Ras Kingdom” - Evidence for the Involvement of p21Ras/MAP Kinase in Autoimmune Diseases
Current Rheumatology Reviews Immunology of VIP: A Review and Therapeutical Perspectives
Current Pharmaceutical Design Lipid-Based Nanocarriers for RNA Delivery
Current Pharmaceutical Design Interferon gama induced Tryptophan Degradation Neuropsychiatric and Immunological Consequences
Current Drug Metabolism Stem Cell-Based Immunomodulation in Type 1 Diabetes: Beyond the Regenerative Approach
Current Pharmaceutical Design Role of the Immune System in Autism Spectrum Disorders (ASD)
CNS & Neurological Disorders - Drug Targets The Study of HLA Class II and Autoimmune Diabetes
Current Molecular Medicine Migraine in Systemic Autoimmune Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Gene Expression Profiles in Human Autoimmune Disease
Current Pharmaceutical Design Cough in Respiratory and Autoimmune Disorders
Current Respiratory Medicine Reviews Myocardial Inflammation in Autoimmune Diseases: Investigation by Cardiovascular Magnetic Resonance and Endomyocardial Biopsy
Inflammation & Allergy - Drug Targets (Discontinued) NF-κB Inhibitors for the Treatment of Inflammatory Diseases and Cancer
Current Medicinal Chemistry NKT Cells: A Regulator in Both Innate and Acquired Immunity
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Toll-Like Receptor Signaling: Emerging Opportunities in Human Diseases and Medicine
Current Immunology Reviews (Discontinued) Cardiovascular Disease in Systemic Lupus Erythematosus: The Role of Traditional and Lupus Related Risk Factors
Current Cardiology Reviews Vitamin D Receptor as a Drug Discovery Target
Mini-Reviews in Medicinal Chemistry Molecular Mimicry in Autoimmune Neurological Disease after Viral Infection
Current Medicinal Chemistry